135 related articles for article (PubMed ID: 15695397)
1. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.
Hashimoto K; Morishige K; Sawada K; Tahara M; Kawagishi R; Ikebuchi Y; Sakata M; Tasaka K; Murata Y
Cancer Res; 2005 Jan; 65(2):540-5. PubMed ID: 15695397
[TBL] [Abstract][Full Text] [Related]
2. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells.
Hashimoto K; Morishige K; Sawada K; Tahara M; Shimizu S; Ogata S; Sakata M; Tasaka K; Kimura T
Biochem Biophys Res Commun; 2007 Mar; 354(2):478-84. PubMed ID: 17240356
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
[TBL] [Abstract][Full Text] [Related]
4. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model.
Takiguchi S; Nishino Y; Inoue K; Ikeda M; Kataoka Y; Matsusue K; Nishiyama K; Iguchi H
Oncol Rep; 2012 Jul; 28(1):111-6. PubMed ID: 22484715
[TBL] [Abstract][Full Text] [Related]
5. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo.
Zhang J; Wang B
Gynecol Oncol; 2006 Oct; 103(1):199-206. PubMed ID: 16624393
[TBL] [Abstract][Full Text] [Related]
7. Dynamic progression of an intraperitoneal xenograft model of human ovarian cancer and its potential for preclinical trials.
Lin XJ; Chen XC; Wang L; Wei YQ; Kan B; Wen YJ; He X; Zhao X
J Exp Clin Cancer Res; 2007 Dec; 26(4):467-74. PubMed ID: 18365540
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
[TBL] [Abstract][Full Text] [Related]
9. Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models.
Kishikawa T; Sakamoto M; Ino Y; Kubushiro K; Nozawa S; Hirohashi S
Invasion Metastasis; 1995; 15(1-2):11-21. PubMed ID: 7545653
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
11. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice.
Lin X; Chen X; Wei Y; Zhao J; Fan L; Wen Y; Wu H; Zhao X
Gynecol Oncol; 2007 Mar; 104(3):540-6. PubMed ID: 17112567
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
14. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
[TBL] [Abstract][Full Text] [Related]
15. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment.
Arlt MJ; Novak-Hofer I; Gast D; Gschwend V; Moldenhauer G; Grünberg J; Honer M; Schubiger PA; Altevogt P; Krüger A
Cancer Res; 2006 Jan; 66(2):936-43. PubMed ID: 16424028
[TBL] [Abstract][Full Text] [Related]
16. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
Kawajiri H; Yashiro M; Shinto O; Nakamura K; Tendo M; Takemura S; Node M; Hamashima Y; Kajimoto T; Sawada T; Ohira M; Hirakawa K
Clin Cancer Res; 2008 May; 14(9):2850-60. PubMed ID: 18451253
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.
Greenaway J; Moorehead R; Shaw P; Petrik J
Gynecol Oncol; 2008 Feb; 108(2):385-94. PubMed ID: 18036641
[TBL] [Abstract][Full Text] [Related]
18. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
[TBL] [Abstract][Full Text] [Related]
20. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro.
Muller S; Migianu E; Lecouvey M; Kraemer M; Oudar O
Anticancer Res; 2005; 25(4):2655-60. PubMed ID: 16080508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
